×
About 2,645 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  956 results

Current status and future prospects of nanomedicine for arsenic trioxide delivery to so...
https://doi.org/10.1002/med.21844
Medicinal Research Reviews; Sönksen M, Kerl K et. al.

Jul 27th, 2021 - Despite having a rich history as a poison, arsenic and its compounds have also gained a great reputation as promising anticancer drugs. As a pioneer, arsenic trioxide has been approved for the treatment of acute promyelocytic leukemia. Many in vit...

RBCK1-TRIB3 decelerated the progression of acute promyelocytic leukemia.
https://doi.org/10.1002/hon.2901
Hematological Oncology; Zhang X, Yu W

Jul 27th, 2021 - Under the differentiation induction therapy with all-trans retinoic acid and arsenic trioxide, nearly 95% of typical acute promyelocyte leukemia (APL), which is characterized by the presence of PML-RARA, patients can be cured. Though its good prog...

see more →

Guidelines  1 results

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  37 results

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT00003861

Feb 6th, 2020 - Objectives: To perform quantitative PCR using known leukemia specific markers in diagnostic bone marrow specimens of patients with newly diagnosed APL and ALL and to correlative pre-treatment copy number with other biologic and molecular features,...

Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03253848

Nov 21st, 2018 - PRIMARY OBJECTIVES: I. To evaluate if the proposed patient care strategy, that includes use of simplified guidelines along with acute promyelocytic leukemia (APL) expert support, decreases the one-month induction mortality rate from 30% to under 1...

Phase III Trial in Acute Promyelocytic Leukemia Patients
https://clinicaltrials.gov/ct2/show/NCT00482833

Oct 22nd, 2018 - Arm I: Induction therapy: Patients receive oral tretinoin twice daily and arsenic trioxide IV over 2 hours on days 1-60. Patients achieving hematological complete remission go on to receive consolidation therapy. Consolidation therapy: Patients re...

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT03151408

Oct 1st, 2018 - This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic...

Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
https://clinicaltrials.gov/ct2/show/NCT01409161

Aug 6th, 2018 - Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if the combination of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuz...

see more →

News  54 results

How to Treat Differentiation Syndrome in APL and AML
https://decisionpoint.medscape.com/oncology/viewarticle/936167

Sep 18th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...

Don't Overlook Treating Older Patients With Acute Promyelocytic Leukemia, Expert Says
https://www.medscape.com/viewarticle/934124

Jul 17th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.medscape.com/viewarticle/917519

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.staging.medscape.com/viewarticle/917519

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

see more →